Bio-Reference Laboratories Inc
Bio-Reference Laboratories — Merger or Acquisition (June 2015)
15 slides from Bio-Reference Laboratories's merger presentation, Jun 10, 2015

Slide 1: Investor Presentation June 2015
Exhibit 99.1 Investor June 2015Presentation

Slide 2: Important Information
Important This business Laboratories Reference STATEMENT/PROSPECTUS THEY IMPORTANT copies the Laboratories’ OPKO’s Participants Bio-Reference transaction. SEC 2014, on These interests, Form documents communication on which documents of WILL January March combination website 10-Q by these Information

Slide 3: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Certain transaction, OPKO’s statements “expect,” “strategy,” All materially timing risk related hire that commercially-viable availability, forward-looking statements. Gathering on information, Form forward-looking the that keyto issues; statements safety personnel; aand 8-K. consummate “

Slide 4: Transaction Overview
Transaction On acquire BRLI OPKO’s The 3Closing June Companies shareholders Bio-Reference of 3, diagnostic 2015 the 2015, Overview transaction expect OPKO will services Laboratories the receive Health, istransaction subject will2.75 Inc. be merged to shares (NYSE: to approval beof with completed OPK

Slide 5: BRLI is a strong corporate culture with demonstrated innovations
54321Bio-Reference Created Built Demonstrated Commercialized strongiscorporate aPositioneda innovations Unique and expanded strong, itself Clinical consistent franchises securely culture Lab in with anAsset clinical oninthe organic multiple cutting testing growth—21 specialty edge and outstanding in

Slide 6: Transaction Rationale
Transaction 1Leverage 52Near-term Utilization Longer-term ofRationale BRLI’s adoption channels of OPKO’s personalized genomic toforaccelerate datatherapy diagnostic theproducts

Slide 7: Transaction Rationale: Near-term
16diagnostic Leverage Extensive ~175 pipeline Transaction BRLIBRLI’s phlebotomy platforms Rationale: patientchannels service ~420 drawsalesNear-term centers tostations accelerate andlocated marketing offer thesynergistic throughout adoption personnel of opportunity theOPKO’s ~5,000 United people dia

Slide 8: Transaction Rationale: Longer-term
72other Transaction Utilization BRLI’s Offers commercial 620+ vast ofarray single genomic Rationale: laboratory ofgene genetics data testsfor in Longer-term along and personalized thegenomics world with numerous OPKO’s data therapy should research panel-based benefit capabilities OPKO tests, includi

Slide 9: OPKO Diversified Portfolio and 4Kscore Supports BRLI fit
OPKO 4Kscore® Supports Claros®1 Diagnostics Vitamin testing Represents Platform Pharmaceuticals Established International Chile Markets Innovative Opportunistic Cardiovascular Investments Anti-virals 8= BRLI Uruguay –fit Datechnology near- immunoassay blood High therapeutics technologies RNAi large

Slide 10: 4Kscore Test: Clinical Utility
Clinical Identifies predictive 91The 4Kscore onlymillion utility blood the value Test actual istest U.S. for based asthat aggressive risk abiopsy Minimally on accurately of three aggressive patients prostate decades Invasive identifies per prostate cancer year; ofAlternative clinical risk over 40–56

Slide 11: The 4Kscore Test Outperforms Other Prostate Cancer Tests
The 4Kscore® AUC PSA Sensitivity Specificity ¹PHI 4³²1— 4Kscore ==0.70, Wang, area Parekh, Catalona 10 WDAUC 0.67 under Test Chevli, et etet al. =Parekh, 2,3 Outperforms 0.82 thePCA3 alcurve alalScientific JK Urol. et 1J2011 D =AUC Urol 0.68 PSA Reports et = 4 and 185(5): al. 0.69 191:1743 Eur 4:1-8

Slide 12: Leverage BRLI National Reach to Accelerate Diagnostic Products Commercialization
Leverage BRLI National Reach to Accelerate Diagnostic Products Commercialization 11

Slide 13: Bio-Reference Routine and Target Markets
Bio-Reference Routine Target Physician Health Geneticists FQHCs Image Automated, HPV Volume, Flow HIV, Key Molecular DNA GCI NextGen Heart Regulatory Studies Each Shared Unique Services: Informatics HepC Genotyping Specialty Cytometry Sequencing Health Directed Markets: Facilities Resources: Special

Slide 14: GeneDx Comprehensive Genetic Testing Capabilities
GeneDx Comprehensive Establish Prenatal Pediatric Cancer *including 13Includes (Next (Non-Invasive Accumulates and aHCM, pathology genomics Postnatal Generation Testing LQT,and partnership Deep Brugada, (Arrays, pre-natal Capabilities Tumor molecular Insights Single Noonan) Sequencing, testing, that

Slide 15: Transaction Addition: Historical and Pro Forma Financials
Transaction BRLI Addition Commercial Historical ($ $851 $47 2012 *Source: For realized 14Note: mm) informational $97 $729 2013 generated $942 BRLI Company in $91 ofand the $629 2014 projected Offers infrastructure $825 financials Pro future. $88mm purposes filings forma OPKO $676 BRLI are operating
Source: SEC EDGAR · 425 filed Jun 10, 2015


